What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to inform investors about the rescheduled date for the special meeting of CVS Health stockholders, which is now set for March 13, 2018. This meeting is where stockholders will vote on the proposed acquisition of Aetna Inc. The filing also announces that the SEC has declared effective the amended registration statement (Form S-4) for the transaction.

When can I expect to receive detailed information about the Aetna acquisition?

The definitive joint proxy statement/prospectus, which contains important information about the proposed transaction between CVS Health and Aetna, will be mailed to CVS Health stockholders and Aetna shareholders beginning on or about February 12, 2018.

Where can I find more detailed information about the Aetna acquisition and related filings?

You can find detailed information in the definitive joint proxy statement/prospectus and other documents filed with the SEC. These documents are available free of charge on the SEC's EDGAR database (www.sec.gov), on CVS Health's investor relations website, and through Aetna's investor relations department.

Are there any specific risks or uncertainties mentioned regarding the Aetna acquisition?

Yes, the filing includes extensive forward-looking statement disclaimers that highlight significant uncertainties and risks. These include potential delays or failure to obtain regulatory approvals, risks related to consummating the transaction, the ability to achieve expected synergies and value creation, and the challenges of integrating Aetna's business. Investors are cautioned not to place undue reliance on these forward-looking statements.

CVS 8-K SEC Disclosure

Summary

This CVS Health (CVS) 8-K filing from February 9, 2018, primarily announces a change in the date for the special meeting of stockholders. The meeting, where stockholders will vote on the proposed acquisition of Aetna Inc., has been rescheduled to March 13, 2018. This adjustment is a procedural update related to securing shareholder approval for a major strategic transaction. The filing also emphasizes that this report is informational and not an offer to sell or solicit any votes or approvals regarding the transaction, directing investors to a more comprehensive registration statement and joint proxy statement/prospectus that has been declared effective by the SEC. Investors should note that the definitive joint proxy statement/prospectus, containing crucial details about the Aetna acquisition, will be mailed to shareholders around February 12, 2018. The filing reiterates the importance of reviewing these documents for complete information regarding the transaction. It also highlights the availability of these documents through the SEC's EDGAR database and CVS Health's investor relations website, along with contact information for obtaining them. The company includes standard forward-looking statement disclaimers, cautioning investors about the uncertainties and risks associated with the transaction and its potential impact.

Key Highlights

1The special meeting date for CVS Health stockholders to approve the Aetna acquisition has been moved to March 13, 2018.
2A registration statement (Form S-4) related to the Aetna merger has been amended and declared effective by the SEC on February 9, 2018.
3The definitive joint proxy statement/prospectus for the CVS Health and Aetna transaction will be mailed to stockholders starting on or about February 12, 2018.
4The filing serves as an informational notice and explicitly states it is not an offer to sell securities or solicitations.
5Investors are strongly urged to read the definitive joint proxy statement/prospectus and other SEC filings for important information regarding the transaction.
6Information on how to obtain copies of relevant SEC filings and contact investor relations for both CVS Health and Aetna is provided.
7The report includes detailed forward-looking statement disclaimers concerning the transaction's risks, uncertainties, and potential impact on future results.

CVS HEALTH Corp 8-K Report, Corporate Update (Feb 9, 2018)

Summary

Key Highlights

Frequently Asked Questions